Publications by authors named "Radha Bathala"
Article Synopsis
- Emerging SARS-CoV-2 sublineages continue to pose a risk for serious COVID-19 disease, particularly as many individuals haven’t been vaccinated in over a year.
- A study evaluated the effectiveness of the mRNA-1273 bivalent vaccine against these circulating sublineages by analyzing confirmed cases and matching them to controls, revealing a decline in vaccine effectiveness over time.
- The findings suggest that periodic revaccination with updated vaccines could be necessary to lower COVID-19-related health issues as the effectiveness of existing vaccines decreases against new variants.
Article Synopsis
- The bivalent mRNA-1273 COVID-19 vaccine, which targets both the original virus and the Omicron BA.4/BA.5 variants, has been authorized to enhance protection against COVID-19.
- A matched cohort study showed that compared to those who only received monovalent vaccines, the bivalent vaccine had a 70.3% effectiveness rate in preventing hospitalizations due to COVID-19.
- The bivalent booster not only sustained strong protection for over three months but also demonstrated effectiveness against medically attended SARS-CoV-2 infections (55.0%) and COVID-19 hospital deaths (82.7%).
Introduction: This observational retrospective matched cohort study evaluated the safety of a prenatal tetanus, diphtheria, acellular pertussis (Tdap) vaccination, Boostrix. We previously reported on the risk of maternal and neonatal outcomes; here we report on the risk of congenital anomalies in infants at birth through 6 months of age.
Methods: The study included pregnant Kaiser Permanente Southern California members.